Moreover, in RADIANCE [64], a phase III trial that enrolled 1320 active relapse-remitting MS patients, most of the adverse events were mild or moderate: in more than 5% of patients treated with ozanimod occurred nasopharyngitis, pharyngitis, urinary tract infections, and increased ALT and γ-glutamyl transferase levels; during dose escalation. The gene discussed is GPT; the disease is urinary tract infection.